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A B S T R A C T
Taste is crucial for patient acceptability and compliance with prescribed medicines, in particular with pediatric
patients. Evaluating the taste of new active pharmaceutical ingredients (APIs) is therefore essential to put in
place adequate taste-masking techniques, if needed, which will lead to acceptable palatable formulations. Thus,
there is an urgent need to develop and optimize taste assessment methods that could be used at diﬀerent stages
of the drug development process. The aim of this study was to investigate the suitability of the rat brief-access
taste aversion (BATA) model as a screening tool for assessment of APIs aversiveness that could predict human
taste responses. Presently, the taste intensity of nine marketed APIs known to have diﬀerent levels of bitter
intensity (quinine hydrochloride dihydrate, 6-n-propylthiouracil, sildenaﬁl citrate, diclofenac sodium, ranitidine
hydrochloride, caﬀeine citrate, isoniazid, telbivudine and paracetamol) was investigated at diﬀerent overlapping
concentrations with two in vivo taste assessment methods: the rat BATA model and human taste panels with the
intention of determining the drugs’ concentrations to produce half of the maximal rating. Overall there was a
strong correlation (R2= 0.896) between rats IC50 and humans EC50 values. This correlation veriﬁes the BATA
model as a rapid and reliable tool for quantitative assessment of API aversiveness. A comparable ranking order
was obtained mainly for high and medium aversive compounds, whereas it was less aligned for weakly aversive
compounds. It was nonetheless possible to propose a classiﬁcation of poor taste intensity determined in rats that
would predict human taste tolerability.
1. Introduction
Taste assessment studies have indirectly become essential during
pharmaceutical development of pediatric medicines due to pediatric
regulations in the United States and European Union [1].
Evaluating the taste of diﬀerent derivatives of new chemical entities
(NCE) such as salts and isomers during the early stages of the drug
development process is therefore of utmost importance to identify taste
aversive compounds at screening stages of pharmaceutical development
and optimize taste-masking strategies to improve patient adherence and
acceptance. Thus, there is a great interest to develop and verify a robust
method to assess the taste of pharmaceutical compounds at early stages
of drug development.
Taste can be assessed with both in vivo and in vitro techniques. The
most widely used and gold standard method to evaluate the taste is by a
human taste panel. However, this method presents many challenges
since the taste assessment of NCEs can only be performed if suﬃcient
toxicological data are available in humans. Unfortunately at the early
stages of the drug development process, toxicological data in humans
are extremely limited or nonexistent. Therefore, human taste data
would not usually be available at the time of writing the Pediatric
Investigation Plan (PIP) and the ﬁnal pediatric dose(s) may not be de-
ﬁned until later in the development program [2]. This will result in very
limited information about pediatric dosage forms in the PIP whose se-
lection is often inﬂuenced by taste-masking opportunities and palat-
ability. Moreover, ethical and/or safety approval can limit human taste
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panels. For example, for several drugs, e.g. cytotoxics, it would be
considered unethical to enroll healthy volunteers, even in swirl and spit
tests. In addition, taste panels are very costly; the training of adult
volunteers and the overall cost for running and setting up a human taste
panel is expensive. Taste trials are also time-consuming and very la-
borious, which can result in taste fatigue of the volunteers and in-
accuracy of the results. The large taste perception variability between
individuals is also another drawback of human taste panels.
Other approaches such as animal models and taste sensors (e-ton-
gues) have shown early promises and optimization of these techniques
was encouraged [3] including industrial application. Among these ap-
proaches, the rodent BATA model has great potential and has already
shown promising results [4–8]. The rodent BATA model is a relatively
simple and fast method to detect successfully in an objective and
quantitative manner the aversive taste of structurally diﬀerent APIs. In
this animal model, mice or rats, are mildly water-deprived and then put
into a special experimental cage. The cage records the number of licks
(lickometer) that the rodents make if the API is presented in diﬀerent
concentrations in several sipper tubes. Animals only have a very short
period of time (between 5 and 10 s) to test each solution. Typically, a
high number of licks indicate a pleasant taste whereas a low number of
licks indicate an aversive taste. With this procedure, a full dose–r-
esponse (concentration–aversion) curve of lick rate can be obtained
over a short period of time with very few animals.
Devantier et al. [4] showed that the relative potencies of four drugs
(quinine, ciproﬂoxacin, clarithromycin, and nystatin) assessed with the
mouse BATA assay (n=16–18) correlated well with the taste in-
tensities evaluated by a trained human taste panel (n=10). Rudnits-
kaya et al. [7] found exactly the same rank order of bitterness predic-
tion for eight drugs (azelastine hydrochloride, caﬀeine, chlorhexidine
digluconate, potassium nitrate, naratriptan hydrochloride, para-
cetamol, quinine hydrochloride and sumatriptan succinate) assessed
with the rat BATA model (n not speciﬁed) and a trained human panel
(n=15). The rat data showed exactly the same rank order of bitterness
prediction as the human panel with a consistent oﬀset of approximately
half-log unit of molar concentration, with rats always rating the bit-
terness lower than humans. They explained this oﬀset by the fact that
rats were encouraged to drink whilst the human panel was not. Noor-
jahan et al. [9] assessed the taste of an iron EDTA complex dissolved in
water as well as formulated in chewable and orodispersible tablets with
a human taste panel (n= 6) and a rat BATA model (n=6). They found
that the correlation coeﬃcient between mean responses of rats and
humans was above 0.5 and concluded a good correlation. However, the
methodology Noorjahan et al. (2014) used for the taste assessment with
rats was diﬀerent from the BATA procedure usually described in pre-
vious published studies [9]. Rats were water-deprived for 24 h and were
then presented to a bottle containing water for 5min; the licking ac-
tivity was taken as standard. After similar water-deprivation duration,
rats were randomly presented to three diﬀerent concentrations of the
drug under assessment. The number of licks taken in ﬁve minutes was
counted and a percentage of licking frequency compared to water was
calculated. This made any cross comparison between studies diﬃcult.
Moreover, additional testing in humans, using other compounds was
encouraged by Devantier et al. [4] to ascertain and complete the data
available in the literature showing that the rodent BATA model is
predictive of human taste data.
Therefore the aim of this study was to conduct a well-designed
prospective rat BATA experiments and human taste panels with ap-
proved compounds. Nine APIs of various levels of aversiveness (i.e.
known for their high to weaker bitterness intensity in human) have
been selected in order to investigate systematically if strong correlation
between both in vivo taste assessment techniques could be established.
This would position the rat BATA model as a taste assessment tool that
could be used during drug development even at an early stage.
2. Material and methods
2.1. Taste solutions
For the rat BATA experiments, quinine hydrochloride dihydrate,
ranitidine hydrochloride, isoniazid, paracetamol and diclofenac sodium
were purchased from Sigma Aldrich (Sigma Aldrich, Dorset, UK).
Caﬀeine citrate and 6-n-propylthiouracil were bought from Fagron
(Fagron, Newcastle upon Tyne, UK) and sildenaﬁl citrate was obtained
from PLIVA d.o.o. (Zagreb, Croatia). For the human taste panels, qui-
nine hydrochloride dihydrate, paracetamol, diclofenac sodium, 6-n-
propylthiouracil, ranitidine hydrochloride were purchased from Fagron
(Fagron, Newcastle upon Tyne, UK). Caﬀeine citrate and sildenaﬁl ci-
trate were purchased from Guinama (Guinama, Valencia, Spain).
Isoniazid was obtained from Macleods Pharmaceuticals (Mumbai,
India). Telbivudine was produced and given by Novartis for both ex-
periments. For the human studies all the drugs were of pharmaceutical
grade Good Manufacturing Practice (GMP) compliant.
For each drug, series of up to six concentrations were tested with the
rat BATA experiments. Up to four concentrations of these were selected
for the human taste panels in order to have concentrations that over-
lapped on the two in vivo panels. The concentration levels for the two
types of taste assessment are listed in Table 1. The diﬀerent solutions
for each drug were prepared by dilutions from the stock solution prior
to each taste assessment session in Buxton® natural mineral water
(Buxton, UK) for the human taste panels and in deionized water for the
rat BATA experiments. The stock solution for each drug was prepared
by dissolving the amount of the corresponding API in a ﬁxed volume of
water under magnetic stirring. Sonication at room temperature was
applied to facilitate dissolution determined by visual inspection of APIs
when needed. All the solutions were tested at room temperature. For
the human taste panels, all extemporaneous preparations were carried
out under the supervision of a registered UK pharmacist following
Standard Operating Procedures (SOPs).
2.2. Rat BATA model
2.2.1. Animals
A total of 20 naive adult male Sprague–Dawley rats (Charles-River,
Kent, UK) were used for these experiments. A cohort of n=10 rats was
used for each BATA experiment. Upon arrival rats received a minimum
of 7 days of acclimatization to the new environment. They were housed
in pairs in standard cages in a room that was maintained at 21 ± 2 °C
with 55 ± 10% humidity and with a 12:12 h light/dark cycle. All
training and testing occurred during the light phase of the cycle.
Animals had free access to chow (Harlan, Oxon, UK) and tap water
except for training and testing periods where a water-restriction sche-
dule occurred. Throughout the experiments, daily food and water
consumption were monitored. As a safety and welfare measure it was
checked that their weight did not drop below 85% of their free-feeding
weight. A washout-period of one week was respected between the dif-
ferent BATA experiments as the rats become naïve again after this time
period and can be used again. All the procedures were carried out in
accordance with Animals (Scientiﬁc Procedures) Act 1986 (Project
License PPL 70/7668).
2.2.2. BATA procedure
The commercially available lickometer “Davis MS-160” from DiLog
Instruments (Tallahassee, Florida, USA) was used for these experiments.
Each rat was water-deprived for 22 h before each session (training and
testing) and was then placed in the lickometer for a maximum session-
length of 40min. After each session, the rodents received tap water for
rehydration for 1 h after experimental day. The ﬁrst days of the protocol
were dedicated to training: on the ﬁrst training day the shutter was
continually open, presenting a single tube containing deionized water;
on the second training session the sixteen tubes contained deionized
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water. The training was followed by two testing days during which each
rat was presented with diﬀerent sipper tubes containing either deio-
nized water or one of the concentrations of the API under assessment.
The trial began when the rat took its ﬁrst lick from the sipper tube, and
ended 8 s later when the shutter closed. A diﬀerent sipper tube was
positioned behind the shutter in preparation for the next trial during
the inter-trial interval. Each trial was intercepted by a water rinse to
minimize carry over eﬀects from the previous solution tested. The order
of presentation of the sipper tubes was randomized and each
concentration was presented 4 times per session. This is an optimized
procedure described in Soto et al. [10].
2.3. Human taste panel study
2.3.1. Participants
A total of twenty one healthy volunteers (10 females and 11 males,
between the ages of 18 and 45 years; average age of the volun-
teers= 27 years) were recruited to conduct the taste assessment of
Table 1
APIs selected and their respective therapeutic use and concentrations (mM) in the rat BATA experiments and human taste panels.
API BATA experiments concentrations (mM) and human taste panels concentrations
(in BOLD)
Solubility in water
(mM)
Quinine hydrochloride dihydrate 0.01 0.03 0.1 0.3 1 3 157.5
6-n-propylthiouracil 0.03 0.3 2.9 6.5
Sildenaﬁl citrate 0.1 0.2 0.4 1.3 2.5 5 6.1
Diclofenac sodium 0.03 0.1 0.3 1 3 10 157.2
Ranitidine hydrochloride 0.2 0.4 0.8 1.6 3.2 4.8 5.1
Caﬀeine citrate 0.3 1 3 10 30 100 245.9
Isoniazid 9.1 18.2 36.5 72.9 145.8 291.7 911.5
Telbivudine 4.1 10.3 20.6 41.3 61.9 82.6 >82.6
Paracetamol 3 5 10 30 50 90 92.6
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quinine hydrochloride dihydrate, sildenaﬁl citrate, diclofenac sodium,
caﬀeine citrate and paracetamol. Thirty one healthy volunteers (8
males and 23 females, between the ages of 18 and 38 years; average age
of the volunteers= 23 years) were enrolled for the taste evaluation of
6-n-propylthiouracil, ranitidine hydrochloride and telbivudine. Twenty
healthy adults (11 females and 9 males, in the age range 18–40 years;
average age of the volunteers= 26 years) assessed the taste of iso-
niazid. All studies were randomized single blinded.
Healthy volunteers included in the studies were able to understand
and speak English. If smokers, they had to forbear smoking at least one
hour before and during all the sessions. Breakfast and neutral lunch (not
spiced, lightly salted) were advised to be taken at least 30min before
the tests. Volunteers were excluded from the studies if they had dete-
rioration of taste or smell, known drug allergies, underwent recent
dental care or were taking a medical treatment (excluding contra-
ceptives) up to 15 days before the tests.
The studies were conducted in accordance with the Declaration of
Helsinki and its amendments, and the protocols were approved by the
Research Ethics Committee at The School of Pharmacy, University
College London.
2.3.2. Taste assessment
Single blind, cross over, single center studies were conducted to
assess the taste of the nine APIs using the “swirl and spit” method. Each
volunteer was given 10mL sample solutions of diﬀerent drug con-
centrations labelled with a randomized code. Subjects were instructed
to swirl the content of each sample in their mouth for 5 s to cover all
buccal surfaces and then spit it out into the plastic cup provided.
Immediately after spitting, volunteers were asked to rate the taste in-
tensity using a computerized questionnaire Qualtrics (Qualtrics, Provo,
US) with 100mm continuous Visual Analogue Scale (VAS) ranging from
not aversive to extremely aversive. Before and after each sample, vo-
lunteers rinsed their mouth with Buxton®mineral water and could have
low salt low fat crackers (Rakusen’s Limited, Leeds, UK) to neutralize
their palate. A minimum interval of 6min (usually 10) was respected
between samples until the previous sample could not be perceived
anymore. Subjects were allowed to immediately re-taste each sample
once, if needed.
The volunteers were asked to attend nine sessions (one session per
drug), two hours in duration each. A minimum of 48-h (usually 1 week)
washout-period was respected in between the sessions in order to re-
duce the burden on volunteers and minimize taste fatigue and contact
with the test samples. One drug at up to four diﬀerent concentrations
was assessed per session. Each solution was given three times in a
randomized order. In order to calibrate the panelists, a sample of bot-
tled water (negative control) was given at the beginning of each session.
In addition, quinine hydrochloride dihydrate at a concentration of
1mM (positive control) was tested by the blinded volunteers during
each session at a diﬀerent time point within the randomization sche-
dule. Each volunteer received the samples in the same randomized
order. All volunteers tasted a total of 14 samples (4 concentrations of
one drug, each tested 3 times and a positive and a negative control) per
session. For each API, the taste intensity of each concentration was
calculated for each volunteer by averaging the ratings obtained for the
three replicates. The average ratings obtained from all the volunteers
were then determined for each concentration.
2.4. Data treatment and analysis
The normality of the data was checked with the Shapiro-Wilk test
for each API. As the data were not normally distributed, the Kruskal-
Wallis test was performed to check if there were any diﬀerences in the
number of licks among the diﬀerent concentrations tested with deio-
nized water. When signiﬁcant, post-hoc analysis was carried out with
Gao et al. non-parametric multiple test [11]. In order to rank the taste
intensities of the diﬀerent APIs an IC50 value which corresponds to the
concentration of the drug that inhibits 50% of the maximum number of
licks compared to the reference, deionized water, was calculated for
each API with an Emax model [10,12].
The same statistical tests were performed for the human taste pa-
nels. Statistical analyses were also performed with the same tests de-
scribed above to check if there were signiﬁcant diﬀerences for the
rating of the positive control between the diﬀerent sessions and be-
tween volunteers. In order to compare the taste intensities obtained for
the nine APIs, an EC50 value which corresponds to the concentration of
the drug that produces half of the maximal rating (1 0 0) was calculated
with the following Emax model:
=
×
+
+E E C
EC C
εmax
Hill
Hill Hill
50
where E is the taste rating, Emax represents the maximum taste rating
ﬁxed to 100, C refers to the concentration of the drug, Hill is the slope
factor aﬀected by the gradient of the curve, EC50 represents the con-
centration which elicits a half-maximal taste rating and ε is the parti-
cipant variability. EC50 values and 95% conﬁdence interval (CI) were
derived from this model for each API. Variance values for each of the
parameters were also obtained as well as the error value, as a reﬂection
of volunteer variability.
Correlation between rat taste data and human taste data was ex-
amined qualitatively by ranking the IC50 and EC50 values and quanti-
tatively by plotting these values on a graph to determine a correlation
factor.
All statistical analyses, boxplots generation and some graphs were
done with R (version 3.0.1). Microsoft Oﬃce Excel 2010 was also used
for the generation of graphs. IC50 and EC50 values were estimated by
using the non-linear mixed eﬀects modelling that was performed using
the software NONMEM® (ICON, Ellicott City, Maryland, version 7.3) in
conjunction with a gfortran (64-bit) compiler using Perl-Speaks
NONMEM ® (PSN, version 4.2.0) as an interface to run NONMEM®.
3. Results
3.1. Rat BATA model
The number of licks was inhibited with increasing concentration for
all nine APIs (Fig. 1). This demonstrated that the rats were able to
detect the aversive taste of all the model drugs. Typically, a high
number of licks indicate a pleasant taste whereas when licks are nearly
completely suppressed it indicates an aversive taste (i.e. a noxious or
punishing stimulus causing avoidance). However, an aversive response
in the BATA model can be caused by an aberrant taste or ﬂavor (e.g.
bitter, but also sour, metallic, burning, spicy…) as well as other aver-
sive physicochemical properties (e.g. pH, viscosity, grittiness). Purpo-
sefully only soluble compounds were used in this work for their known
bitter taste attribute in human more or less intense.
The range of concentrations completely inhibiting the number of
licks was covered for almost all the APIs tested. The concentrations
chosen for quinine hydrochloride dihydrate, caﬀeine citrate and iso-
niazid enabled to produce a full concentration-response curve with a
nearly complete inhibition of licks with the highest concentration
(around 90% inhibition). 6-n-propylthiouracil, diclofenac sodium and
sildenaﬁl citrate inhibited 80% of the licks with the highest con-
centration. Ranitidine hydrochloride reduced the number of licks
compared to water by nearly 60% at the highest concentration.
Paracetamol only inhibited 38% of the licks compared to water at the
highest concentration, 90mM, which was the highest concentration
that could be tested due to the solubility limit. Finally, telbivudine
managed to decrease the number of licks compared to water by 35%
only; a larger range of concentrations could have been explored for this
API. The screening of the range of concentrations inhibiting the number
of licks in rats was done ﬁrst. This was done irrespectively of the
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therapeutic dose but starting close to maximum API solubility assuming
that the maximum concentration that can be solubilized in water would
be what the taste buds would be exposed to. For each API, four out of
the six API concentrations tested in rats were also tested in the human
taste panels to correlate the data head to head. For more accuracy API
dissolved in saliva would be better however, saliva ﬂow and composi-
tion (simulated vs un-simulated) varies therefore it is diﬃcult to strictly
mimic [13].
Quinine hydrochloride dihydrate and 6-n-propylthiouracil were the
most aversive compounds (to the left of the graph).
A group of 4 compounds occupied the center of the graph (medium
aversiveness).
Finally a group of 3 compounds sat on the right of the graph and
were deemed the least aversive.
3.2. Human taste panel
For each drug, 63 data points were recorded per concentration
averaging the data from all the volunteers (Fig. 2). As expected, the
ratings increased with increasing concentrations for each drug. The
volunteers were able to diﬀerentiate between the aversiveness of the
nine drugs at diﬀerent concentrations.
Brieﬂy, for quinine hydrochloride dihydrate, 6-n-propylthiouracil,
diclofenac sodium, ranitidine hydrochloride, isoniazid, telbivudine and
paracetamol, all the concentrations were found to be signiﬁcantly dif-
ferent from one another and the controls (p < 0.05) indicating the
sensitivity of the panelists to the diﬀerent concentrations of these APIs.
Quinine hydrochloride dihydrate, 6-n-propylthiouracil and diclofenac
sodium concentrations were separated by a three-fold increment, which
seems to be an adequate interval for the separation of the concentra-
tions that can be distinguished by humans. The concentrations chosen
for paracetamol were not all following a three-fold increment. The two
lowest concentrations of paracetamol were slightly diﬀerent from each
other with a p-value that was at the limit of the signiﬁcance level
(p= 0.032) and only seven volunteers were able to clearly diﬀerentiate
5mM from 10mM. This showed a reduced sensitivity of the panelists to
small increments (two-fold increment) in concentrations that were low.
Similarly, the two lowest concentrations of sildenaﬁl citrate, 0.2 and
0.4 mM, were not signiﬁcantly diﬀerent from each other (p=0.168).
As for paracetamol, this could be due to the small increment between
these two concentrations. It can be noticed from the graph that for all
the volunteers, only the highest concentration was found to have an
extremely aversive taste, similar to the quinine control with a p-value
close to the level of signiﬁcance (p=0.040). All the concentrations of
caﬀeine citrate were signiﬁcantly diﬀerent from one another
(p < 0.05) and the highest concentration (10mM) was rated as
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Fig. 1. Average percentage inhibition of licks
(/8 s) (± SEM) compared to water for quinine
hydrochloride dihydrate , 6-n-pro-
pylthiouracil , sildenaﬁl citrate , di-
clofenac sodium , ranitidine hydrochloride
, caﬀeine citrate , isoniazid ,
telbivudine , and paracetamol for
n= 10 rats. *First concentration signiﬁcantly
diﬀerent (p < 0.05) compared to the reference,
deionized water. Signiﬁcance based upon non-
parametric Kruskal-Wallis test results using
median.
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Fig. 2. Average taste ratings (± SEM) for qui-
nine hydrochloride dihydrate , 6-n-pro-
pylthiouracil , sildenaﬁl citrate , di-
clofenac sodium , ranitidine hydrochloride
, caﬀeine citrate , isoniazid ,
telbivudine , and paracetamol for
humans. *First concentration signiﬁcantly dif-
ferent (p < 0.05) compared to the reference,
mineral water. Signiﬁcance based upon non-
parametric Kruskal-Wallis test results using
median.
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aversive as the quinine control (1 mM) by the panel (p= 0.592).
3.3. Comparison of rat BATA experiments and human taste panels
Despite a slight shift between rat and human responses, a strong
correlation (R2= 0.8963) was observed between the two panels
(Fig. 3), the resulting equation being IC50= 1.0469(EC50)0.9101. The
correlation plot of in vivo/in vivo taste intensities was done for eight
APIs excluding paracetamol as no IC50 value could be obtained in rats
for paracetamol. The IC50 and EC50 values were generated based on rat
and human taste panels for the selected APIs, except for paracetamol
and telbivudine where no IC50 value could be calculated in rats
(Table 2). Rats assessed quinine hydrochloride dihydrate as the most
aversive API followed by 6-n-propylthiouracil, sildenaﬁl citrate, rani-
tidine hydrochloride, diclofenac sodium, caﬀeine citrate, isoniazid,
telbivudine and paracetamol. This rank order is in agreement with the
ranking predicted based on the nine concentration-response curves
(Fig. 1). The human sensory data showed a similar rank order of
aversive taste prediction as the rat BATA model for the high and
medium aversive compounds (Fig. 3). However, for low aversive
compounds, the IC50 ranking order between rats and humans slightly
diﬀers showing a lower correlation between the two taste assessment
techniques (quinine hydrochloride dehydrate∼ 6-n-propylthiour-
acil > diclofenac sodium∼ sildenaﬁl citrate > ranitidine hydro-
chloride > caﬀeine citrate, paracetamol > isoniazid > telbivudine
in humans).
EC50 values obtained from the human taste studies were generally
within less than one-half log unit of molar concentration of those de-
rived from the rat BATA model (Table 2).
3.4. Proposed classiﬁcation for prediction of human taste response based on
rat BATA data
The proposed classiﬁcation made to predict human taste response
based on rat BATA data is shown on Table 3.
In order to verify the aforementioned, 4 compounds not included in
the building proposed classiﬁcation were used to calculate the EC50
from the IC50 (with equation IC50= 1.0469(EC50)0.9101). This calcu-
lated EC50 was then compared to the measured EC50. The BATA and
human taste panel methodologies used to generate the EC50 and IC50
were identical to the one described in this paper. Table 4 shows the
outcome of this exercise.
For these 4 compounds the rat data were 100% predictive of the
human level of aversiveness of the API. Please note that despite quinine
Fig. 3. In vivo/in vivo correlation plot between EC50 values (mM) for human panels and IC50 values (mM) for rat panels for 8 APIs.
Table 2
Rat IC50 values and human EC50 values for quinine hydrochloride dihydrate, sildenaﬁl citrate, diclofenac sodium, caﬀeine citrate and paracetamol in mM (n.d.: not
determined; * this value was derived from a graph and is an approximation).
Drug Rat IC50 and
corresponding 95% CI
(mM)
Human EC50 and
corresponding 95% CI
(mM)
Log IC50 –
Log EC50
Comparison with literature
(IC50)
Comparison with literature (EC50)
Quinine hydrochloride
dihydrate
0.08 (0.01–0.16) 0.26 (0.14–0.37) −0.51 ∼0.1 (Rudnitskaya et al.
[7])
∼0.01mM (calculated) for quinine
hydrochloride; Rudnitskaya et al. [7]
*0.658mM for quinine sulfate; Devantier et al.
[4]
6-n-propylthiouracil 0.22 (0.12–0.35) 0.22 (0.12–0.29) 0.00 / /
Sildenaﬁl citrate 2.00 (1.56–2.45) 1.58 (1–2) 0.10 / /
Ranitidine hydrochloride 4.02 (2.82–5.22) 2.73 (1.96–4.40) 0.17 / /
Diclofenac sodium 4.91 (1.17–10.99) 1.51 (1–2) 0.51 / /
Caﬀeine citrate 7.76 (5.62–9.90) 5.01 (4–6) 0.19 ∼50mM with caﬀeine
base (Rudnitskaya et al.
[7])*
∼5mM with caﬀeine base (Rudnitskaya et al.
[7])*
Isoniazid 80.94 (54.93–106.95) 259 (80.05–437.95) -0.51 / /
Telbivudine 187.45 (74.15–300.75) 88.34 (56.23–120.48) 0.33 / /
Paracetamol n.d. 41.3 (32–50) n.d. No IC50 found by
Rudnitskaya et al. [7]*
∼10mM (Rudnitskaya et al. [7])*
> 7 mM (Albertini et al. [21])
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being used as a bitter model drug there is actually very few product as bitter
as it is.
4. Discussion
In this study, the taste intensity of nine model drugs was in-
vestigated at diﬀerent concentrations with two diﬀerent methods: the
rat BATA model and a human taste panel. A strong correlation
(R2=0.8963) was found between the two in vivo taste assessment
methods for high and medium aversive compounds. The potencies
(EC50s) determined in humans were essentially the same as those de-
termined in rats suggesting that the rat BATA model is predictive of
human taste assessment for these categories of compounds. For less
aversive compounds, the ranking order between rats and humans
slightly diﬀers showing a lower correlation between the two taste as-
sessment techniques. Nevertheless, the potencies determined in humans
were classiﬁed in the same taste intensity categories as those de-
termined in rats suggesting that the rat BATA model is predictive of
human taste assessment for these compounds as well. It is interesting to
note that despite quinine used as a bitter reference compound, very few
compounds are as bitter as quinine.
Rodents possess about 30% more genes than humans [14] and
probably have a wider spectrum of bitter sense detection and thus are
likely to be able to detect bitter molecules with very diverse chemical
structure [15]. Based on previous works undertaken with rodents, some
species are more appropriate for some type of studies than others. Mice
genomic map has been widely studied due to ease of genetic manip-
ulation. Rats for their part have long been the general species of choice
for behavioral studies, assessment of their behaviors are well mapped
and well understood [16]. Due to their larger size, rats drink more than
mice. Stellar and Hill observed that their rate of drinking is however the
same, regardless of their level of thirst, and is about 1.5mL/min. Rats
drink at a rate of about 6–7 licks/s [17]; therefore it is estimated that
the rats receive approximately 4 μL per lick. It is then expected to have
a more consistent pattern of drinking data using rats as they have a
higher capacity to drink than mice. In addition, due to their bigger size,
there is an easier handling of rats compared to mice. Rats were there-
fore chosen to conduct the BATA experiments. Bitter taste signaling is
mediated by type 2 taste receptor (T2R), a family of G protein-coupled
receptors. A comparison between rat and mouse genomes led to the
functional analysis of the entire rodent T2R repertoire. A total of 36
intact T2R genes and 7 pseudogenes have been found in the mouse and
rat [15] compared to ∼25 genes and 11 pseudogenes identiﬁed in
humans [18]. They are all located on mouse chromosomes 15, 2 and 6
[19] and rat chromosomes 2, 3 and 4. Two chromosomes only comprise
a single T2R gene (in rats and mice) whereas the third chromosome,
chromosome 6 and 4, respectively in mouse and rat, contains the rest of
the T2R genes and pseudogenes in multiple clusters, which are orga-
nized almost identically in both species. Despite some discrepancies,
rodent T2R genes are highly conserved in terms of genomic organiza-
tion, chromosomal localization, number of genes, sequence homology
between the orthologs, tissue expression, ligand speciﬁcity and receptor
function. This suggests that rodent T2Rs are evolved under similar
dietary pressure and share bitter sensing functions in the lingual and
gastrointestinal systems [15]. It is interesting to note that a higher
number of rodent T2R genes exist compared to humans.
The EC50 values obtained in humans were generally within one-half
log unit of molar concentration of those derived from the rat BATA
experiments. These ﬁndings are in accordance with the results obtained
by Devantier et al. [4] who found that the relative potencies of four
drugs (quinine, ciproﬂoxacin, clarithromycin and nystatin) assessed in
the mouse BATA assay matched the taste intensities evaluated by a
trained human taste panel. In their study, the absolute potencies of the
drugs in humans were also all within one-half log unit of molar con-
centration derived from the mouse BATA and did not diﬀer statistically.
The present results also correlate well with the ﬁndings from Rudnits-
kaya et al. [7] who compared the taste data obtained for eight drugs
(azelastine hydrochloride, caﬀeine base, chlorhexidine digluconate,
potassium nitrate, naratriptan hydrochloride, paracetamol, quinine
hydrochloride and sumatriptan succinate) with the rat BATA model and
a trained human taste panel. They found that the rat panels showed
exactly the same rank order of bitterness prediction as the human pa-
nels with a consistent oﬀset of approximately half-log unit of molar
concentration.
From the results obtained in the present study, it was shown that the
BATA model is reliable to predict the taste in case a human panel is not
available or possible. However no general rule can be made whether
rats or humans are more sensitive to the aversive taste of compounds. It
has been found in this study that for quinine hydrochloride dihydrate
and isoniazid, rats were more sensitive to the aversive taste than hu-
mans whereas for sildenaﬁl citrate, ranitidine hydrochloride, diclofenac
sodium, caﬀeine citrate, telbivudine and paracetamol, humans were
more sensitive than rats. Nevertheless, the oﬀsets were generally within
one-half log unit of molar concentration except for 6-n-propylthiouracil
where exactly the same potencies where found in rats and humans.
Devantier et al. [4] found that mice were more sensitive than humans to
quinine and clarithromycin and less sensitive to ciproﬂoxacin, which
reinforced the present ﬁndings. However, Rudnitskaya et al. [7] found
that there was an approximately consistent oﬀset around half-log unit
of molar concentration, with rats always rating the bitterness lower
than humans. They explained this oﬀset by the fact that rats were en-
couraged to drink as they were water-deprived whilst the human panel
not. Analyzing their methodology deeper for the comparison of the rat
BATA data and the human taste data, it has been noticed that the
concentrations tested were not necessarily the same for both panels and
that for some compounds, e.g. quinine hydrochloride, the concentra-
tions chosen in both panels were not even overlapping. Moreover, for
some of the drugs they tested, the range of concentrations chosen was
lower for the human panels than for the rat panels. Therefore, this can
be one of the reasons why they always found that rats were less
Table 3
Classiﬁcation proposed to predict human taste response based
on rat BATA data.
IC50 categories Level of aversiveness
0–0.1mM Extremely aversive
0.1–1mM Moderately aversive
1–10mM Mildly aversive
10–100mM Weakly aversive
Table 4
Veriﬁcation of the proposed classiﬁcation to predict human taste response based on rat BATA data with 4 compounds [A and B: REC 4612/009; C: REC 4612/017; D:
REC 4612/012].
Compound IC50 (mM) Level of aversiveness Calculated EC50 (mM) Level of aversiveness Measured EC50 (mM) Level of aversiveness
A 13.63 Weakly aversive 11.28 Weakly aversive 27 Weakly aversive
B 1.31 Mildly aversive 1.34 Mildly aversive 3.6 Mildly aversive
C 2.02 Mildly aversive 1.98 Mildly aversive 1.29 Mildly aversive
D 90.00 Weakly aversive 62.87 Weakly aversive 35.70 Weakly aversive
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sensitive to the bitterness than humans.
In order to be able to have a direct comparison rats/human of taste
intensity, the concentrations used in both were always overlapping.
However, fewer concentrations could be tested in humans (maximum
four compared to six in rats) to allow having three repeats for each
concentration and two controls (positive and negative), which are es-
sential to produce accurate results and verify the consistency of the
data. Caution was also taken to minimize number of samples assessed
per session to minimize taste fatigue [9,20]. Therefore, for each API,
generally four out of the six concentrations assessed in the rat BATA
model and covering a large range of concentrations (chosen below, at
and above IC50 if not limited by solubility e.g. paracetamol) were se-
lected for the human sensory analysis. It was always ensured that the
concentrations chosen were well below the level causing toxicological
eﬀect in humans to make sure that in the unlikely event of an accidental
ingestion of a single sample, the maximum amount of drug that parti-
cipants could be exposed to would be below the acceptable daily intake
(ADI). Selecting the same concentrations in both panels was essential to
compare the results in an accurate manner.
5. Conclusions
The taste of nine model APIs having diﬀerent degree of aversiveness
(bitterness), has been assessed using two diﬀerent in vivo methods, the
rat BATA model and human taste panels. The present research showed
an overall strong correlation between rats and humans taste response
for the eight APIs assessed: the stronger the aversiveness, the stronger
the correlation. This is an important milestone towards the use of this
animal model as an in vivo taste assessment tool to inform the drug
development including taste masking. A similar ranking order was
obtained with both in vivo taste assessment methods for high and
medium aversive compounds with a consistent oﬀset of one half-log
unit of molar concentrations between IC50 and EC50 values. However,
for low aversive compounds, the ranking order between rats and hu-
mans slightly diﬀers showing a lower correlation between the two taste
assessment techniques. Nevertheless, the potencies determined in hu-
mans were classiﬁed in the same taste intensity categories as those
determined in rats suggesting that the rat BATA model is predictive of
human taste assessment for these compounds as well. These results
indicate that the rat BATA model could be used as a taste assessment
screening tool of APIs in early development. A proposed classiﬁcation
was made to predict human taste response based on rat BATA data.
The present new data completes the few data available in the lit-
erature comparing the taste of rodents and humans and reinforces the
assertion that the rat BATA model is predictive of human taste assess-
ment and could be used as a taste assessment screening tool of APIs in
early development. In future work, additional APIs having diﬀerent
taste intensity levels (covering other IC50/EC50 values) should be as-
sessed in rats and humans to enrich the present database in order to
validate the correlation found in the present study.
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